American Heart Journal
Volume 138, Issue 3 , Pages 387-389 , September 1999

β-Blocker withdrawal: The song of Orpheus

References 

  1. Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H. Can β-blocker therapy be withdrawn from patients with dilated cardiomyopathy?. Am Heart J. 1999;138:456–459
  2. Swedberg K, Hualmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 1980;44:134–142
  3. Waagstein F, Caidahl K, Wallentin I, Bergh C, Hjalmarson A. Long term β-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawl and readministration of metoprolol. Circulation. 1989;80:551–563
  4. Shand DG, Wood AJJ. Propranolol withdrawal syndrome—why?. Circulation. 1978;58:202–203
  5. Slome R. Withdrawal of propranolol and myocardial infarction. Lancet. 1973;1:156
  6. Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med. 1975;293:416–418
  7. Alderman EL, Coltart J, Wettach GE, Harrison DC. Coronary artery syndromes after sudden propranolol withdrawal. Ann Intern Med. 1974;81:625–627
  8. Eichhom EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation. 1996;94:2285–2296
  9. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, et al.  Changes in gene expression in the intact human heart. Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100:2315–2324
  10. Bristow MR, Gilbert EM, Lowes BD, Minobe WA, Shakar SF, Quaife RA, et al.  Changes in myocardial gene expression associated with β-blocker-related improvement in ventricular systolic function [abstract]. Circulation. 1997;96:I-92
  11. Mann DL, Kent RL, Parsons B, Cooper GIV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790–804
  12. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154–1161
  13. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al.  Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310–1320
  14. Katz A. the cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med. 1994;121:363–371
  15. Myers JH, Horwitz LD. Hemodynamic and metabolic response after abrupt withdrawal of long-term propranolol. Circulation. 1978;58:196–201
  16. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483–490
  17. Gilligan DM, Chan WL, Stewart R, Oakley CM. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol. 1991;68:766–772
  18. Nattel S, Rangno RE, Van Loon G. Mechanism of propranolol withdrawal phenomena. Circulation. 1979;59:1158–1164
  19. Grant JA, Scrutton MC. Positive interaction between agonists in the aggregation response of human blood platelets: interaction between ADP, adrenaline and vasopressin. Br J Haematology. 1980;44:109–125
  20. Frishman WH, Christodoulou J, Weksler B, Smithen C, Killip T, Scheidt S. Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. Am Heart J. 1978;95:169–179
  21. Packer M. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. Am J Cardiol. 1997;80:46L–54L
  22. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997;79:794–798
  23. CIBIS-II investigators and committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  24. MERIT-HF group . Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/ZL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–2007
  25. Fesmire SI, Marcoux LG, Lyyski DS, Sprague MK, Kennedy HL, Eichhorn EJ. Effect of selective vs non-selective beta-blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Am J Cardiol. 1999;84:350–354

☆ From the Department of Internal Medicine (Cardiology Division), The University of Texas Southwestern and Dallas VA Medical Centers.

☆☆ Reprint requests: Eric J. Eichhorn, MD, Cardiac Catheterization Laboratory (ILIA2), University of Texas Southwestern and Dallas Veterans Administration Medical Centers, 4500 S. Lancaster, Dallas, TX 75216.E-mail: Eichhorn@Ryburn.swmed.edu

★ Am Heart J 1999;138:387-9.

★★ 0002-8703/99/$8.00 + 0   4/1/92526

PII: S0002-8703(99)70134-1

American Heart Journal
Volume 138, Issue 3 , Pages 387-389 , September 1999

Article Tools